Company announcement – No. 42 / 2026

Zealand Pharma – Notification of holding of treasury shares

Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares.

As of 21 August 2026, the Company holds nominally 3,597,842 treasury shares, corresponding to 5.03% of the total share capital and 5.03% of the total voting rights in Zealand Pharma. In accordance with Section 85 of the Danish Companies Act, the Company cannot exercise any voting rights attached to its treasury shares.

About Zealand Pharma

Zealand Pharma A/S (NASDAQ:ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Contacts

Eric Rojas (Investors)

Vice President, Head of Investor Relations

Zealand Pharma

Email: erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)

Vice President, Corporate Communications and Media Relations

Zealand Pharma

Email: rjamesowens@zealandpharma.com

Andreas Hylleberg Mølleskov (Media)

Director, External Communications

Zealand Pharma

Email: ahylleberg@zealandpharma.com